EUVIMEDEUVIMED entdecken
Crossref

Osimertinib, platinum, and etoposide for patients with metastatic EGFR / TP53 / RB1 -mutant lung cancers at risk for histological transformation

Lena Morrill Gavarró iD, Monica F Chen iD, Álvaro Quintanal Villalonga iD, Yufei Deng iD, Liancheng Lu iD, Britney Forsyth, Sahil Sahni iD, Eric G Sun iD, Swanand Rakhade iD, Rania G Aly, Meng Wang, Amin Sabet iD und 24 weitere

Science Translational Medicine · 11.11.2026 · 18 (875)

DOI: 10.1126/scitranslmed.aee6618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 11.11.2026. Verfasst von Lena Morrill Gavarró und 35 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Tumor Suppressor Protein p53, Mutation, Aniline Compounds. Die Arbeit nennt 66 Literaturangaben. Gefördert von: NCI NIH HHS, National Institutes of Health, NIH Office of the Director.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although EGFR inhibitors are highly effective for treating EGFR- mutant lung adenocarcinomas ( EGFR + LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR + LUAD at high risk of transformation ( TP53 / RB1 -deficient) and treated them with first-line osimertinib combined with platinum and etoposide. Despite the addition of SCLC-directed chemotherapy, nearly half of patients (5 of 11) underwent SCLC transformation, with median progression-free survival of 11 months and overall survival of 33 months. Genomic and single-cell transcriptomic profiling of patient samples revealed clinical and subclinical plasticity associated with TP53 / RB1 comutations, including histological transformation to SCLC, as well as mesenchymal and squamous histologies. These changes in plasticity were linked to progressive disruption of the RB pathway, leading to altered chromatin accessibility and induction of neuronal differentiation and epithelial-to-mesenchymal transition transcriptional programs, further intensified by osimertinib treatment. These findings provide insights into the role of plasticity in mediating drug tolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsTumor Suppressor Protein p53MutationAniline CompoundsEtoposidePlatinumAcrylamidesCell Transformation, NeoplasticHumansErbB ReceptorsIndolesPyrimidinesNeoplasm MetastasisSmall Cell Lung CarcinomaEpithelial-Mesenchymal TransitionFemaleUbiquitin-Protein LigasesRetinoblastoma Binding Proteins

Substanzen

ErbB ReceptorsTumor Suppressor Protein p53IndolesPyrimidinesAniline CompoundsosimertinibEtoposidePlatinumAcrylamidesEGFR protein, human

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
  • Columbia University, New York, NY 10027, USA.

ORCID-Profile: Lena Morrill Gavarró, Monica F Chen, Álvaro Quintanal Villalonga, Yufei Deng, Liancheng Lu, Sahil Sahni, Eric G Sun, Swanand Rakhade, Amin Sabet, Prithviraj Solanki, Christina Wilson, Natasha Rekhtman, Sam Tischfield, Jake June-Koo Lee, Linda Ahn, Clare Wilhelm, Amanda Pupo, Christina Falcon, Andrea Arfe, Katherine Panageas, Ignas Masilionis, Ojasvi Chaudhary, Ronan Chaligne, Esther Redin, Eric Gardner, Dana Pe'er, Charles M Rudin, Joseph M Chan, Helena A Yu

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • NIH Office of the Director
  • National Cancer Institute
  • Damon Runyon Cancer Research Foundation
  • American Society of Clinical Oncology
  • Concern Foundation
  • Lung Cancer Research Foundation

Zitieren

APA

Gavarró, L. M., Chen, M. F., Villalonga, Á. Q., Deng, Y., Lu, L., Forsyth, B., Sahni, S., Sun, E. G., Rakhade, S., Aly, R. G., Wang, M., Sabet, A., Solanki, P., Wilson, C., Rekhtman, N., Tischfield, S., Lee, J. J., Moses, K., Ahn, L., …, & Yu, H. A. (2026). Osimertinib, platinum, and etoposide for patients with metastatic EGFR / TP53 / RB1 -mutant lung cancers at risk for histological transformation. Science Translational Medicine, 18(875). https://doi.org/10.1126/scitranslmed.aee6618

Vancouver

Gavarró LM, Chen MF, Villalonga ÁQ, Deng Y, Lu L, Forsyth B, et al. Osimertinib, platinum, and etoposide for patients with metastatic EGFR / TP53 / RB1 -mutant lung cancers at risk for histological transformation. Science Translational Medicine. 2026;18(875). doi:10.1126/scitranslmed.aee6618

BibTeX
@article{Gavarr2026,
  author = {Gavarró, Lena Morrill and Chen, Monica F and Villalonga, Álvaro Quintanal and Deng, Yufei and Lu, Liancheng and Forsyth, Britney and Sahni, Sahil and Sun, Eric G and Rakhade, Swanand and Aly, Rania G and Wang, Meng and Sabet, Amin and Solanki, Prithviraj and Wilson, Christina and Rekhtman, Natasha and Tischfield, Sam and Lee, Jake June-Koo and Moses, Khadeja and Ahn, Linda and Wilhelm, Clare and Pupo, Amanda and Falcon, Christina and Arfe, Andrea and Panageas, Katherine and Kris, Mark G and Manoj, Parvathy and Masilionis, Ignas and Chaudhary, Ojasvi and Chaligne, Ronan and Redin, Esther and Gardner, Eric and Wang, Xinjun and Pe'er, Dana and Rudin, Charles M and Chan, Joseph M and Yu, Helena A},
  title = {Osimertinib, platinum, and etoposide for patients with metastatic EGFR / TP53 / RB1 -mutant lung cancers at risk for histological transformation},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {875},
  doi = {10.1126/scitranslmed.aee6618}
}
Kostenlos starten →